Objective : A dural arteriovenous fistula (DAVF) generally refers to a vascular malformation of the wall of a major venous sinus. These lesions have diverse symptoms according to the location and venous drainage, and require multidisciplinary treatment. We report on our experience and analyze the treatment outcome of intracranial DAVFs for a nine-year period.
INTRODUCTION
Dural arteriovenous fistulas (DAVFs) are pathologic shunts that develop between the dural arteries and dural venous sinuses, meningeal veins, or cortical veins. They account for approximately 10% to 15% of Castaigne and Djindjian 5) proposed an acquired etiology in the late 1970's. However, the benign nature of these lesions was challenged principally by Cognard et al. 8) and Borden et al., 3) who proposed that the clinical aggressiveness of DAVFs was dependent on the degree of cortical venous reflux.
Intracranial DAVFs can be classified according to the type of venous drainage. The classification scheme developed by Cognard et al. 8) and Borden et al. 3) is the one most commonly used (Table 1) In this study, we analyze clinical characteristics of intracranial DAVFs with respect to hemorrhage and discuss current strategies for treatment of DAVFs. 
MATERIALS AND METHODS

RESULTS
Clinical presentation
A majority of patients with DAVFs presented with non-aggressive symptoms. Thirty six patients (38%)
had pulsatile tinnitus and bruit, 15 patients (16%) had ocular and visual symptoms, 12 patients (13%) had mild to moderate headache, and five patients (5%)
were found incidentally.
Twenty seven patients (28%) presented with aggressive symptoms. Fifteen patients (16%) had intracranial hemorrhage, nine patients (9%) had seizure, and three patients (3%) had dementia, trigeminal neuralgia, and aphasia. Table 4 . 
Complications
In the surgery, one patient with a DAVF located in the right parasagittal convexity developed hemiparesis just after a microsurgical interhemispheric approach.
In the endovascular embolization, one patient with transverse-sigmoid sinus DAVF developed an intracranial hemorrhage during an interventional procedure. DAVFs can also present with aggressive symptoms, such as cranial neuropathies and/or quadriparesis.
22)24)
In this study, the most common symptoms of cavernous sinus DAVF were ocular symptoms (40%) and aggressive neurologic symptoms were rare; there was On the other hand, aggressive neurological symptoms correlated well with the venous drainage pattern of transverse-sigmoid sinus DAVFs because these occurred only in Borden type II and III. In this study, besides the venous drainage pattern, the location of a transverse-sigmoid sinus was found to be a factor affecting intracranial hemorrhage. Therefore, due to the low rate of spontaneous regression and the relatively high rate of aggressive symptoms, all transverse-sigmoid sinus DAVFs are considered to require treatment. 21) Aggressive neurologic symptoms were also seen in the majority of SSS DAVFs (62%) and tentorial DAVFs (Table 3) . However, in our study, in DAVFs with cortical venous drainage, a 23% hemorrhage rate and 41% aggressive symptom rate were suggested. Brown et al. 4) pointed out that 2% of Borden type I, 40% of (Table 3) In this study, two patients with an anterior cranial fossa DAVF underwent successful surgery and achieved complete occlusion. Due to the difficult endovascular access route, combination therapy of embolization and surgery was performed in the SSS DAVF and the tentorial DAVF. In this study, complete occlusion using embolization and surgery was achieved in 80% of SSS DAVFs and 100% of tentorial DAVFs.
Ushikoshi et al. 37) reported that DAVFs with Borden type III can be treated by embolization and surgery with a high rate of cure. The efficacy of this combined approach for DAVF ablation has been contended at nearly 100%, however, the risk of morbidity and mortality remains considerable. 10)12)18) We treated nine pa-tients with Borden type II and III DAVFs using a combination of embolization and surgery, and achieved complete occlusion in 89% of them, without complications (Table 5 ).
In our study, 43 patients with DAVFs were treated by GKS or a combination of GKS and embolization.
The early results from another report have been encouraging, with obliteration rates as high as 93% for combined endovascular embolization and GKS, but have also demonstrated obliteration rates as low as 50% when only GKS is used. 32) 39) The cumulative cure rate for cavernous sinus DAVFs approached 75% at 24 months when only GKS was used, which was much better than that of other intracranial DAVFs. 39) In our study, the obliteration rate reached 54% when only GKS was used and 83% when GKS was combined with endovascular embolization (Table 5) 
